Jack Lepping

Retired! Board memberships: MJH Life Sciences, Linnaeus Therapeutics, Lep Foundation for Youth Education, Ruesch Cancer Center at Georgetown.

[Applied Clinical Trials @Clin_Trials]

The FDA has opened the door for MRD-based accelerated approval in multiple myeloma.

The question is: Are sponsors prepared?

Register today and gain insights to help navigate this evolving regulatory landscape: https://t.co/oHTDwLBZRu

[HCPLive @HCPLiveNews]

New at #ENDO2026: In an interview with Elena Christofides, MD, we discussed the structure of the CRESSA trial and how endocrinologists can remain conscious of monitoring the HPA axis in patients receiving corticosteroids.

Watch now: https://t.co/VZCFe5p1GE

[HCPLive @HCPLiveNews]

While #SDPA2026 is done, we've got more coverage of the meeting coming out!🌟

Have you caught up with the biggest stories/interviews with leaders in #dermatology?

🔗If not, view here: https://t.co/qsIx5gRMFL

[HCPLive @HCPLiveNews]

Check out our iPub® Speed to Cure: Simplifying the standard of care for HCV. Our panel of experts will explore nontraditional models of care. Watch now. https://t.co/QvfC1JD037

[PER @gotoPER]

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions https://t.co/qqrq3oCG7u

[PER @gotoPER]

New and Emerging Strategies of Obesity Management https://t.co/D0ZhtpW2xH

[PER @gotoPER]

Are you up to date on the latest management strategies in LGSOC?

This free CME activity explores how to identify LGSOC, reviews the current standard of care, including surgery, chemotherapy, targeted therapies, and hormonal therapies.

Watch now: https://t.co/N5gvMZy4VW

[CancerNetwork® @CancerNetwrk]

🚨 ICYMI: This week's podcast featured highlights from our #ASCO26 X Space on #mmsm #leusm and #lymsm.

Tune in for a discussion with:
⭐ Marc J. Braunstein, MD, PhD (@docbraunstein)
⭐ Sofia Zahid, MD (@SofiaZahid26)

https://t.co/zsOSXuIzJO

🎙️ Available now Spotify and Apple Podcasts!

[CancerNetwork® @CancerNetwrk]

The external data monitoring committee recommended termination of the KEYNOTE-D46/EVOKE-03 study after sacituzumab govitecan plus pembrolizumab did not reach statistical significance for PFS in previously untreated metastatic PD-L1+ NSCLC.

⬇️ Read more ⬇️
https://t.co/2Inj77RuFu

#lcsm #NSCLC #oncology

[CancerNetwork® @CancerNetwrk]

In the phase 3 HEALER/KN026-003 trial, anbenitamab plus HB1801:

⭐ Significantly prolonged PFS vs THP
⭐ Showed favorable trend for OS vs THP

📆 Full results will be shared at an upcoming conference

https://t.co/2TRNsg2UjZ

#bcsm #BreastCancer #oncology

[MJH Life Sciences® @MJHLifeSciences]

It was an honor to host Justin Wren for our Q2 Training Day.
We’re thankful for the uplifting message, powerful story, and meaningful perspective he shared with our team.
#MJHLifeSciences #TrainingDay #Leadership #Resilience

[MJH Life Sciences® @MJHLifeSciences]

We are proud to announce our Gold-level Cigna Healthy Workforce Designation™ award. Thank you to our leadership team and all associates who made this award possible!

#MJHLifeSciences #EmployeeWellness #CignaHealthyWorkforce

[Pharmacy Times @Pharmacy_Times]

As the treatment landscape for HER2-positive gastroesophageal adenocarcinoma continues to evolve, pharmacists remain at the center of translating new evidence into practice.

Matthew Arango, PharmD, reflects on the key principles pharmacists should keep top of mind when managing HER2-positive GEA and discusses how emerging HER2-targeted therapies, biomarkers, and clinical data may continue to expand the pharmacist's role in patient care.

What developments do you think will have the biggest impact on pharmacy practice in the years ahead?

Explore the full Peer Exchange for more expert insights on the future of HER2-positive GEA care: https://t.co/IIpP2bvIG7

[Pharmacy Times @Pharmacy_Times]

June is Migraine & Headache Awareness Month.

Swipe through to see the top pharmacist-recommended products from the 2025 OTC Guide.

The 2026 OTC Guide results are coming later this month. Follow Pharmacy Times to see what pharmacists recommend next.

[Pharmacy Times @Pharmacy_Times]

🚨 Heart disease, kidney disease, obesity, and diabetes are no longer being viewed as separate problems.
The first-ever guideline for cardio-kidney-metabolic (CKM) syndrome calls for earlier screening and more coordinated care to identify risk before serious complications occur.
🔗 https://t.co/8Qngd52M0H
#HeartHealth #KidneyDisease #Diabetes #Obesity #PreventiveCare #PharmacyTimes #PublicHealth

[Cure GI Cancers @RueschCenter]

Research by: @benweinbergmd, @RuthHe12, @anita_turk, @OAranha_MDPHD, @ReetuMukherjiMD, @mnoel3232, @marshalj23, Hongkun Wang, @DrKatePedersen and others at #ASCO26. Poster #105 Abstract #4122. @LombardiCancer.
Learn More: https://t.co/IuIrKGPpw1

[Cure GI Cancers @RueschCenter]

Research by @benweinbergmd, Alexander Lekan, Zoe Malchiodi, @allisonoconn, Ming T. Tan, Xue Geng, @mnoel3232, @RuthHe12, @ReetuMukherjiMD, @marshalj23, Martin Gutierrez, Princess Jones, Rashmi M. Deshpande, Louis M. Weiner at #ASCO26. Poster #184 Abstract #4201.@LombardiCancer.
Learn More: https://t.co/T0YJST5sQB

[Silas Inman @SilasInman]

Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer https://t.co/AYs8tgXwVw

[Silas Inman @SilasInman]

AZ is joining the GLP1 market: Elecoglipron Advances to Phase 3, Shows Phase 2 Weight Loss, Glycemic Data https://t.co/Mem4KIPz3B

[CURE Today @cure_today]

Join us in Miami Beach, FL, on June 17, for CURE’s
#EducatedPatient Update in MBC.
📆June 17 | 5:30 PM ET
📍Mount Sinai Medical Center

In partnership with @MountSinaiMiami & @SusanGKomen

Save your spot: https://t.co/bQJNNANuP0

#mbc #educatedpatient #cure